Inari Medical (NARI) Q4 2022: International Revenue Jumps 144% as Market Expansion Accelerates
Inari Medical’s Q4 delivered robust double-digit growth, powered by strong procedure volume and a breakout in international markets. The company’s disciplined sales force expansion and differentiated clinical programs are driving share in a still underpenetrated $6B venous thromboembolism (VTE) market. With new product launches and clinical data releases on deck, Inari is positioning for continued leadership amid rising competition and evolving care standards.
Summary
- International Expansion Surges: Global sales grew sharply, reflecting early traction in Europe and new market entries.
- Clinical Evidence and Product Pipeline Differentiate: Registry data and new launches reinforce Inari’s technology and market position.
- Operating Leverage Focus Intensifies: Management signals a shift toward profitability while sustaining growth investments.
Business Overview
Inari Medical develops and commercializes minimally invasive devices for treating venous diseases, with a primary focus on mechanical thrombectomy for deep vein thrombosis (DVT) and pulmonary embolism (PE). The company’s two flagship systems, ClotTriever (DVT removal) and FlowTriever (PE intervention), generate the majority of revenue, supported by a growing portfolio including ProTrieve (DVT protection) and InThrill (small vessel thrombectomy). Inari’s business model relies on both per-procedure pricing and incremental value-add device sales, with a growing presence in international markets.
Performance Analysis
Inari posted 30% year-over-year revenue growth in Q4, reaching the upper end of pre-announced guidance, with sequential growth of 12%. This expansion was underpinned by strong procedure growth across both ClotTriever and FlowTriever product lines. The revenue mix remained consistent, with FlowTriever contributing 68% and ClotTriever and other systems at 32%, a split that has held steady year-over-year.
Gross margin compressed to 87.8% from 90.1% a year ago, reflecting the addition of new products to the toolkit and a per-procedure pricing model that introduces incremental costs. Operating expenses rose sharply, driven by sales force expansion and higher R&D and SG&A, resulting in a net loss for the quarter and full year. International revenue stood out, with Q4 growth of 144% year-over-year and full-year international sales of $9.4 million, primarily from Europe.
- International Revenue Breakout: Global sales are now disclosed separately, highlighting the company’s commitment to overseas expansion and the early-stage nature of market penetration abroad.
- Operating Leverage Emerges: Sales force productivity gains and moderated hiring signal a pivot toward efficiency after a period of aggressive investment.
- Product Mix and Margin Pressure: New launches and international sales are diluting gross margin, but management is actively pursuing pricing and operational initiatives to mitigate this trend.
Cash and investments remain strong at $326.4 million, providing ample runway for continued R&D, market development, and global expansion. Management reaffirmed full-year revenue guidance, signaling confidence in both core and adjacent market growth levers.
Executive Commentary
"Our end markets are large and remain highly underpenetrated. And while we continue to view competition in VTE as potentially additive to our efforts to develop the market, make no mistake, as the clear market leader, we're highly confident in our ability to maintain our competitive position relative to devices with inferior safety or efficacy profiles."
Drew Hikes, President and Chief Executive Officer
"We invested aggressively in our growth drivers. We've leveraged these investments to deliver robust growth, build important capabilities, and ultimately better serve our patients. Looking ahead to 2023, we are working to reduce the rate of operating expense growth while leveraging our previous investments. We expect to show sequential progress related to these efforts as we move through the year."
Mitch Hill, Chief Financial Officer
Strategic Positioning
1. Sales Force Expansion and Account Penetration
Inari’s disciplined sales force growth, now at over 280 US territories, is paired with a focus on productivity and deeper penetration of existing accounts. The company’s VT Excellence program, a hospital partnership initiative, is driving adoption and repeatable market development, aiming to replicate the systematization seen in stroke and myocardial infarction care pathways.
2. Clinical Evidence and Differentiation
Robust clinical data from the Clout and Flash registries demonstrate superior clot removal with minimal blood loss compared to competitors, providing a foundation for physician confidence and market leadership. Upcoming studies like FLAME (high-risk PE) and ongoing RCTs (Defiance and Peerless) are designed to further entrench Inari’s devices as standards of care and expand addressable markets.
3. Product Portfolio Expansion
Multiple product launches, including ProTrieve and InThrill, are targeting new patient populations and clinical scenarios. ProTrieve addresses protection during complex DVT procedures, while InThrill opens up small vessel and AV fistula interventions, together representing substantial incremental TAM (total addressable market). The chronic venous disease toolkit, including the upcoming RevCore, aims to unlock the largest unmet need segment.
4. International Growth
International sales are accelerating, especially in Europe, with new market entries in Asia-Pacific and Latin America. Early pricing dynamics in Europe have been favorable, though margin dilution is expected as this segment scales. Regulatory and go-to-market strategies are in development for Japan and China.
5. Competitive Response and Market Development
Management views new entrants as potential market expanders, given the low overall penetration of mechanical thrombectomy in VTE. However, head-to-head clinical and economic differentiation remains a core defense, with no observed loss of accounts to recent competitor launches.
Key Considerations
This quarter marks a strategic inflection as Inari balances aggressive market expansion with a renewed focus on operational discipline and profitability. The company’s ability to sustain growth while managing cost structure and margin pressure will be critical as competition intensifies and the product portfolio broadens.
Key Considerations:
- Global Market Penetration Remains Early: Both US and international VTE intervention rates are low, leaving ample room for procedure growth and share gains.
- Clinical Data Pipeline Drives Adoption: Upcoming FLAME study and ongoing RCTs could shift guidelines and accelerate uptake, particularly in intermediate-risk PE.
- Margin Management in Spotlight: Gross margin will trend lower as new products and international sales scale, but pricing power and cost initiatives are being deployed to offset this drift.
- Operating Leverage Transition: Sales force productivity and moderated hiring are expected to yield sequential profitability improvement into 2024.
- Product Launch Execution Is Key: Success of ProTrieve, InThrill, and future launches will determine incremental revenue and margin impact.
Risks
Margin erosion from new product launches and international expansion could outpace pricing and cost controls, pressuring profitability. Competitive trialing, particularly from well-capitalized rivals, may intensify, though management expresses confidence in clinical differentiation. Regulatory delays or setbacks in key markets like China and Japan also present risks, as do slower-than-expected uptake of new products or changes in reimbursement dynamics.
Forward Outlook
For Q1 2023, Inari did not provide specific intra-quarter guidance but noted that January and February were among the strongest months in company history.
- Full-year 2023 revenue guidance reaffirmed at $470 to $480 million.
Management expects:
- Continued robust US and international growth, with new product launches contributing modestly in the early phases.
- Sequential progress on operating leverage and a clear commitment to sustained profitability by the first half of 2024.
Takeaways
Inari’s Q4 results underscore the company’s leadership in a large, underpenetrated market, with clinical evidence, product innovation, and disciplined expansion as key levers.
- International Growth Accelerates: Record overseas sales and a formal revenue breakout signal a new phase of global opportunity, with Europe leading and Asia-Pacific on the horizon.
- Clinical and Operational Differentiation: Data and physician feedback reinforce Inari’s technology advantages, while operational focus shifts toward profitability without sacrificing growth.
- Future Watchpoints: Investors should monitor the impact of FLAME and other clinical studies on guideline adoption, as well as the margin trajectory as the product and geographic mix evolves.
Conclusion
Inari Medical enters 2023 with momentum, backed by strong core growth, early-stage international expansion, and a robust innovation pipeline. The company’s ability to translate clinical leadership and operational investments into sustained profitability will define its next phase of value creation.
Industry Read-Through
Inari’s rapid international growth and clinical evidence-driven strategy highlight the importance of real-world data and physician engagement in medtech adoption, especially in markets with entrenched legacy therapies. Competitors in mechanical thrombectomy and broader interventional vascular markets should note the operational discipline and pricing strategies deployed to sustain margin in the face of portfolio broadening and geographic expansion. The company’s experience also signals that early-stage markets can support both expansion and new entrants, but clinical differentiation and hospital economics will remain decisive in shaping long-term winners.